Zhuye Jie;Huihua Xia;Shi Long Zhong;Qiang Feng;Shenghui Li;Suisha Liang;Huanzi Zhong;Zhipeng Liu;Yuan Gao;Hui Zhao;Dongya Zhang;Zheng Su;Zhiwei Fang;Zhou Lan;Junhua Li;Liang Xiao;Jun Li;Ruijun Li;Xiaoping Li;Fei Li;Huahui Ren;Yan Huang;Yangqing Peng;Guanglei Li;Bo Wen;Bo Dong;Ji Yan Chen;Qing Shan Geng;Zhi Wei Zhang;焕明 杨;Jian Wang;Jun Wang;烜 张;Lise Madsen;Susanne Brix;光 宁;Xun Xu;Xin Liu;Yong Hou;Huijue Jia;Kunlun He;Karsten Kristiansen
China National GeneBank;Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research;Guangdong Provincial Cardiovascular Institute;Guangdong Provincial People's Hospital;Shenzhen Engineering Laboratory of Detection and Intervention of Human Intestinal Microbiome;University of Copenhagen;Shandong University;BGI-Shenzhen;University of Chinese Academy of Sciences;South China University of Technology;General Hospital of People's Liberation Army;Washington University St. Louis;China Association for Science and Technology;James D. Watson Institute of Genome Sciences;Macau University of Science and Technology;Institute of Marine Research;Technical University of Denmark
发表时间：2017-12-1
期 刊：Nature Communications
语 言：English
U R L： http://www.scopus.com/inward/record.url?scp=85031012310&partnerID=8YFLogxK
The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.
Scopus度量
| 年份 | CiteScore | SJR | SNIP |
|---|---|---|---|
| 1996 | |||
| 1997 | |||
| 1998 | |||
| 1999 | |||
| 2000 | |||
| 2001 | |||
| 2002 | |||
| 2003 | |||
| 2004 | |||
| 2005 | |||
| 2006 | |||
| 2007 | |||
| 2008 | |||
| 2009 | |||
| 2010 | |||
| 2011 | 2.5 | 3.137 | 2.543 |
| 2012 | 6.5 | 5.866 | 3.172 |
| 2013 | 9.4 | 6.206 | 2.906 |
| 2014 | 10.9 | 6.41 | 3.05 |
| 2015 | 13.3 | 6.287 | 2.817 |
| 2016 | 16.9 | 6.414 | 2.869 |
| 2017 | 18.5 | 6.582 | 2.93 |
| 2018 | 18.1 | 5.992 | 2.86 |
| 2019 | 18.1 | 5.569 | 2.847 |
| 2020 | 19.8 | ||
| 2021 |
相似文献推荐
微信
科技工作者之家
京公网安备11010202008424号
